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Background: 123I-labelled 2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT)
imaging is a diagnostic tool to help differentiate dementia with Lewy bodies (DLB) from Alzheimer’s disease
(AD). However, in animals, cholinesterase inhibitors (ChEi) have been reported to reduce radioligand binding
to the striatal dopamine transporter. As ChEi are frequently used in people with dementia, it is important to
determine whether their use affects 123I-FP-CIT uptake in the striatum.
Objective: To clarify whether chronic ChEi therapy modulates striatal dopamine transporter binding
measured by 123I-FP-CIT in patients with AD, DLB and Parkinson’s disease with dementia (PDD).
Design: Cross sectional study in 99 patients with AD (nine on ChEi, 25 not on ChEi), DLB (nine on ChEi, 19
not on ChEi) and PDD (six on ChEi, 31 not on ChEi) comparing 123I-FP-CIT striatal binding (caudate, anterior
and posterior putamen) in patients receiving compared with those not receiving ChEi, correcting for key
clinical variables including diagnosis, age, sex, Mini-Mental State Examination score, severity of
parkinsonism and concurrent antidepressant use.
Results: As previously described, 123I-FP-CIT striatal uptake was lower in DLB and PDD subjects compared
with those with AD. Median duration of ChEi use was 180 days. 123I-FP-CIT uptake was not significantly
reduced in subjects receiving ChEi compared those not receiving ChEi (mean percentage reduction: AD 4.3%;
DLB 0.7%; PDD 6.1%; p = 0.40). ChEi use did not differentially affect striatal 123FP-CIT uptake between patient
groups (p = 0.83).
Conclusions: Use of ChEi does not significantly influence the ability of 123I-FP-CIT imaging to distinguish AD
from DLB.
S
ingle photon emission computed tomography (SPECT)
with the ligand 123I-labelled 2b-carbomethoxy-3b-(4-
iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT),
which binds to the dopamine transporter (DAT), has been
shown to be useful in discriminating dementia with Lewy
bodies (DLB) from Alzheimer’s dementia (AD).1 2
However, the utility of 123I-FP-CIT imaging may be under-
mined if individuals are taking medications that affect the
striatal binding of 123I-FP-CIT, particularly if such agents
differentially influence 123I-FP-CIT striatal binding between
DLB and AD. A significant class of drugs which might impact
on 123I-FP-CIT binding in these patient groups are cholinester-
ase inhibitors (ChEi). In the monkey, DAT availability, assessed
by [11C] b-CFT positron emission tomography (PET), was
reported to be acutely suppressed in a dose dependent manner
by the ChEi donepezil.3 Direct evidence that cholinesterase
inhibition modulates DAT function in humans is currently
lacking.
To determine whether chronic ChEi therapy influences
striatal DAT binding by 123I-FP-CIT in humans, we compared
123I-FP-CIT striatal binding in patients with AD, DLB and
Parkinson’s disease with dementia (PDD) treated with ChEi
with those not receiving these agents.
METHODS
Data from 93 subjects from a previous study published by our
group were analysed.2 Data from a further six subjects (five
with DLB and one with PDD) were also included.
Detailed SPECT methodology and analysis are described
elsewhere.2 In brief, striatal binding was determined from the
striatal:occipital activity ratios. Regions of interest (ROIs) were
positioned at three distinct locations within the striatum to
obtain measurements of the caudate, anterior putamen and
posterior putamen. Striatal:occipital activity ratios for the three
ROIs for each hemisphere were determined as:
123I-FP-CIT bindingcaudate, anterior putamen, posterior putamen =
Striatal uptakecaudate, anterior putamen, posterior putamen /
Occipital uptake
For analysis, an average of left and right hemisphere 123I-FP-
CIT uptake for each ROI was used.
Analysis of the effect of medications on 123I-FP-CIT striatal
binding was tested using multivariate analysis of covariance
(MANCOVA) with fixed factors of sex, diagnosis and con-
current antidepressant use, and covariates of age, Mini-Mental
State Examination score, Unified Parkinson’s Disease Rating
Scale, subsection III (UPDRS III) score and duration of illness.
In subjects on medications, time on ChEi was added into the
model as an additional covariate.
RESULTS
Subject characteristics are summarised in table 1. Groups were
broadly matched for sex, age and cognitive impairment
Abbreviations: AD, Alzheimer’s disease; ChEi, cholinesterase inhibitors;
DAT, dopamine transporter; DLB, dementia with Lewy bodies; 123I-FP-CIT,
123I-labelled 2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl)
nortropane; PDD, Parkinson’s disease with dementia; PET, positron
emission tomography; ROIs, regions of interest; SPECT, single photon
emission computed tomography; UPDRS III, Unified Parkinson’s Disease
Rating Scale, subsection III
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although the PDD group were younger than the AD (p,0.001)
and DLB (p,0.02) groups. As expected, the DLB and PDD
groups had higher UPDRS III scores than the AD subjects (DLB
vs AD, p,0.001; PDD vs AD, p,0.001). Analysis of illness
duration showed that PDD subjects had a longer illness
duration compared with AD (p,0.001) and DLB (p,0.001)
subjects. Subject demographics for age, sex, degree of cognitive
impairment or UPDRS III score did not differ by use of ChEi.
Subjects with PDD taking ChEi had a longer illness duration
(p = 0.05) and a trend to have been on their medication longer
than subjects in the AD and DLB groups (p = 0.07). Concurrent
antidepressant use was similar between diagnostic groups
(p = 0.47) and cholinesterase status (p = 0.70).
Figure 1 shows graphically the mean and 95% CI for the
striatal:occipital binding ratios of 123I-FP-CIT for the three ROIs
in subjects receiving ChEi and subjects not receiving ChEi.
Striatal uptake differed between the groups (MANCOVA, Wilks
Lambda, df = 6, F = 3.87, p = 0.001), after adjusting for fixed
factors and covariates; specifically, the PDD group had lower
striatal uptake in all three areas compared with the DLB
(p,0.001) and AD (p,0.001) groups. DLB subjects had
significantly lower uptake in all three striatal regions compared
with the AD subjects (p,0.001). With regard to the effects of
ChEi, across all three ROIs, there was a tendency for uptake to
be reduced in those subjects on ChEi (mean magnitude of
striatal:occipital binding reduction: AD 4.3%; DLB 0.7%; PDD
6.1%) but this reduction was not significant in the corrected
multivariate analysis (MANCOVA, Wilks Lambda, df = 3,
F = 0.99, p = 0.40). There was no significant interaction
between the use of ChEi and diagnostic group in terms of
striatal 123I-FP-CIT uptake (MANCOVA, Wilks Lambda, df = 3,
F = 0.47, p = 0.83). Similarly, antidepressant use did not
significantly affect 123I-FP-CIT uptake (MANCOVA, Wilks
Lambda, df = 3, F = 0.28, p = 0.84) and there was no
significant interaction between ChEi and concurrent antide-
pressant use (MANCOVA, Wilks Lambda, df = 3, F = 0.26,
p = 0.96). In subjects taking ChEi, duration of prior ChEi use
did not impact significantly on 123I-FP-CIT uptake (MANCOVA,
Wilks Lambda, df = 3, F = 0.60, p = 0.54).
DISCUSSION
123I-FP-CIT SPECT imaging has been shown to have high
sensitivity and specificity in distinguishing AD from DLB, even
in DLB patients without clinical parkinsonism.1 2 4 5 The main
finding of this study is that concurrent use of ChEi does not
significantly affect the results from 123I-FP-CIT imaging.
There are conflicting reports on whether ChEi influence DAT
binding by radioligands. In rats, Kilbourn et al showed that
treatment with phenserine, a ChEi, produced a 24% decrease in
radioligand DAT binding of d-threo-[3H]methylphenidate.6 In
contrast, in a biodistribution study in rats, Knol et al did not
observe any effect of donepezil or rivastigimine on DAT imaging
with 123I-FP-CIT.7 Relevant to the present study is the primate
study of Tsukada et al who observed that a single dose of
Table 1 Demographic and neuropsychological data on subjects studied using 123I-FP-CIT SPECT
Variable
Subjects
p Value
(diagnosis
group)
p Value
(ChEi
status)
With AD With DLB With PDD
No ChEi
(n = 25) ChEi (n = 9)
No ChEi
(n = 19) ChEi (n = 9)
No ChEi
(n = 31) ChEi (n = 6)
Sex (M/F) 10/15 5/4 13/6 4/5 20/11 6/0 0.08 0.66
Age (y) 79.1 (5.7) 78.5 (5.6) 74.3 (6.6) 79.4 (6.7) 72.3 (5.3) 70.3 (6.3) ,0.001 0.56
MMSE score (maximum score 30) 17.9 (5.1) 15.6 (4.0) 15.6 (6.1) 18.0 (4.3) 19.0 (5.2) 20.2 (7.9) 0.15 0.72
CAMCOG (maximum score 107) 59.8 (15.9) 49.3 (21.7) 59.6 (16.4) 61.5 (8.2) 63.8 (14.8) 64.3 (16.4) 0.09 0.64
UPDRS III (maximum score 108) 4.9 (3.9) 7.4 (7.0) 27.8 (14.1) 20.1 (9.8) 37.3 (11.6) 36.7 (11.8) ,0.001` 0.44
Duration of Illness (months) 33.2 (20.1) 38.3 (13.5) 33.6 (25.9) 27.6 (25.0) 65.1 (39.0) 133 (96.0) ,0.001 0.011
Time on ChEi prior to 123I-FP-CIT (days)* NA 99 (26–733) NA 124 (35–520) NA 388 (128–577) 0.07 NA
Antidepressant use (n) 2 3 3 1 8 1 0.47 0.70
AD, Alzheimer’s disease; CAMCOG, Cambridge Cognitive Examination; ChEi, acetylcholinesterase inhibitor; DLB, dementia with Lewy bodies; 123I-FP-CIT, 123I-labelled
2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane; MMSE, Mini-Mental State Examination; NA, not applicable; PDD, Parkinson’s disease with Lewy
body dementia; UPDRS III, Unified Parkinson’s Disease Rating Scale subsection III: motor function.
Data are mean (SD) unless stated otherwise.
*Data expressed as median (minimum to maximum).
Gabriel post hoc tests showed that subjects with AD were older than PDD subjects (p,0.001) and subjects with DLB were older than PDD subjects (p,0.02).
`Mann–Whitney post hoc tests showed that subjects with AD had lower UPDRS III scores than those with DLB (p,0.001) or PDD (p,0.001). Subjects with DLB had lower
UPDRS III scores than those with PDD (p,0.01).
Mann-Whitney post hoc tests showed that subjects with PDD had longer illness duration than AD (p,0.001) or DLB (p,0.001).
1Interaction between diagnosis group and ChEi status was significant (p,0.01). Mann-Whitney post hoc tests showed that subjects with PDD and on ChEi had longer
illness duration than PDD subjects not on ChEi (p = 0.05).
Figure 1 Striatal:occipital activity for subjects with Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia
(PDD) in the caudate nucleus, anterior putamen and the posterior putamen comparing subjects receiving cholinesterase inhibitors (ChEi) and those not
receiving ChEi. Values are means (95% CI).
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donepezil suppressed DAT availability, assessed using [11C] b-
CFT PET.3 Tsukada et al proposed that this effect may occur
either via transynaptic mechanisms or presynaptic receptor
modulation. This observation is contrary to that observed in the
present study. Dosage levels of ChEi in the study of Tsukada et
al and the present study were comparable. Possible explana-
tions for this discrepancy include the following.
Differences in ligands
123I-FP-CIT reaches striatal binding equilibrium 3–6 h after
injection. In contrast, [11C]b-CFT reaches peak equilibrium
within 1 h after injection.8 Furthermore, 123I-FP-CIT has an
affinity for the serotonin reuptake transporter.9 Therefore, it is
feasible that differences in affinity and kinetic binding profiles
between [11C] b-CFT and 123I-FP-CIT ligand may account for
the disparity between our results and those of Tsukada et al.3
Differences in species, age and pathological status
Human DAT differs morphologically and functionally from DAT
in other species.10 11 Consequently, species differences in terms
of ligand binding may be apposite. In addition, the monkeys
used by Tsukada et al were young and healthy. Age related
reductions in DAT have been noted in humans in both SPECT
and PET studies and specifically in Lewy body disease, where
there are significant losses of striatal DAT.4 5 12 13 Therefore, it is
possible that suppression of DAT activity as a result of ChEi use
may not have been apparent in the present study because of
floor effects.
Differences in duration of exposure to ChEi
The monkeys studied by Tsukada et al were treated acutely with
an intravenous bolus of donepezil.3 In contrast, in our study,
patients had been receiving oral ChEi for a median of 180 days
(minimum 26 days). It is plausible that prolonged exposure to
ChEi might lead to a compensatory upregulation in DAT as a
result of increased acetylcholine and therefore negation of any
acute suppression. This is, in part, supported by evidence that
the chronic administration of nicotinic agonists such as
nicotine increase DAT mRNA expression in rats.14
Furthermore, Padilla et al observed in rats that repeated bolus
doses of chlorpyrifos, a ChEi insecticide, caused an increase in
DAT density in the striatum after 6 months, although they did
not observe any changes in DAT density with chronic low dose
exposure to chlorpyrifos.15
Increases in 123I-b-CIT striatal binding have been observed in
subjects treated with the serotonin reuptake inhibitors,
citalopram and paroxetine.16 17 This increase may be caused by
an interaction between serotonin and dopamine systems in the
striatum16 or increased 123I-b-CIT availability secondary to
peripheral serotonin reuptake transporter blockade and
decreased central serotonin reuptake transporter availability.17
Therefore, it could be argued that depression of striatal 123I-FP-
CIT uptake by ChEi might potentially be masked by concurrent
antidepressant use. However, the proportions of subjects taking
antidepressants in the present study were similar in those
taking (20.8%) and not taking (17.3%) ChEi. Furthermore, we
did not observe any significant interaction between antide-
pressant use and concurrent ChEi use in terms of 123I-FP-CIT
striatal binding.
The cross sectional nature of the present study cannot
exclude subtle changes in 123I-FP-CIT striatal uptake as a result
of chronic use of ChEi. In addition, while currently most 123I-
FP-CIT imaging is carried out in patients with established
dementia and on long term ChEi, the present study cannot
determine the effect of acute/short term ChEi use. To answer
these issues, a prospective blinded study comparing 123I-FP-CIT
binding before and after ChEi administration would be
required. However, our study has important implications as it
means that the prior use of ChEi does not affect the diagnostic
discriminant validity of 123I-FP-CIT imaging. This has clinical
importance as it suggests that it is not necessary to withdraw
ChEi prior to diagnostic 123I-FP-CIT imaging, an action which
could cause deleterious effects on patient’s cognitive function
and behaviour.
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